Private debt and infrastructure will remain South Korean institutional investors’ favorite alternative asset classes for the second straight yea...
Jan 29, 2024 (Gmt+09:00)
South Korea's bioplasma technology firm Plasmapp announced on Friday that it has signed a product supply contract worth 16.4 billion won ($12.3 mill...
Sep 08, 2023 (Gmt+09:00)
As economic uncertainties grow amid rate hikes and inflation, South Korean institutional investors are eyeing direct lending for safer investment an...
Jul 06, 2022 (Gmt+09:00)